Clinical trial
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
NCT00095654
Study timeline
Study start (unknown)2001-07-01Date precision: month
Registry last updated2009-11-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Impaired Glucose Toleranceunresolved
Cardiovascular Diseaseunresolved
Glucose Metabolism Disordersunresolved
Interventions
RamiprilDRUG · verified · RxNorm: ramipril
RosiglitazoneDRUG · verified · RxNorm: rosiglitazone
Sponsors & collaborators
Gerstein, Hertzel, MDlead sponsor
Canadian Institutes of Health Research (CIHR)collaborator
Aventis Pharmaceuticalscollaborator
GlaxoSmithKlinecollaborator
Wyeth is now a wholly owned subsidiary of Pfizercollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00095654 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.